Expert Review of Endocrinology & Metabolism最新文献

Adrenocortical tumors and hereditary syndromes. 肾上腺皮质肿瘤和遗传综合征。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-21 DOI: 10.1080/17446651.2024.2431748

Kanakamani Jeyaraman, Paola Concolino, Henrik Falhammar

{"title":"Adrenocortical tumors and hereditary syndromes.","authors":"Kanakamani Jeyaraman, Paola Concolino, Henrik Falhammar","doi":"10.1080/17446651.2024.2431748","DOIUrl":"https://doi.org/10.1080/17446651.2024.2431748","url":null,"abstract":"Introduction: Adrenocortical tumors (ACTs) are frequently encountered in clinical practice. They vary in clinical and biological characteristics from nonfunctional to life threatening hormone excess, from benign to highly aggressive malignant tumors. Most ACTs appear to be benign and nonfunctioning. It has been controversial how these apparently benign and nonfunctioning tumors should be monitored. Over the past few decades, significant advances have been made in understanding the regulation of growth and tumorigenesis in adrenocortical cells. Defining the molecular pathomechanisms in inherited tumor syndromes led to the expansion of research to sporadic ACTs. Distinct molecular signatures have been identified in sporadic ACTs and a potential genomic classification of ACT has been proposed.Areas covered: In this review, we discuss the various adrenocortical pathologies associated with hereditary syndromes with special focus on their molecular pathomechanisms, the understanding of which is important in the era of precision medicine.Expert opinion: Identifying the molecular pathomechanisms of the adrenocortical tumorigenesis in inherited syndromes has led to the understanding of the alterations in different signaling pathways that help explain the wide variations in the biology and behavior of ACTs.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-19"},"PeriodicalIF":2.7,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review. 与分化型甲状腺癌的起源和演变有关的环境因素：叙述性综述。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1080/17446651.2024.2377687

José Paz-Ibarra, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave

{"title":"Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review.","authors":"José Paz-Ibarra, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave","doi":"10.1080/17446651.2024.2377687","DOIUrl":"10.1080/17446651.2024.2377687","url":null,"abstract":"Introduction: The global incidence of thyroid cancer (TC) has increased in the last decades. While improvements in diagnosis may contribute, overdiagnosis is also a possibility. This review focuses on the epidemiology, risk factors, and immune microenvironment associated with differentiated TC (DTC).Areas covered: A search was conducted in Scielo, Scopus, and EMBASE databases, involving 72 articles. TC is the most common endocrine neoplasm, with DTC form being predominant. Its incidence has globally risen, particularly among women aged over 45. Endogenous risk factors for DTC include genetic disorders, race, age, female gender, obesity, and type 2 diabetes mellitus. Environmental risks involve ionizing radiation, whether through therapeutic treatment or environmental contamination from nuclear accidents, iodine deficiency, endocrine disruptors, residence in volcanic areas, environmental pollution, and stress. The use of anti-obesity medications remains controversial. The tumor's immune microenvironment is the histological space where tumor cells interact with host cells, crucial for understanding aggressiveness. Immunotherapy emerges as a promising intervention.Expert opinion: Recent advances in DTC management offer transformative potential, requiring collaborative efforts for implementation. Emerging areas like precision medicine, molecular profiling, and immunotherapy present exciting prospects for future exploration, shaping the next era of diagnostic and therapeutic strategies in thyroid cancer research.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"469-477"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress in managing children with achondroplasia. 管理软骨发育不全儿童的进展。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1080/17446651.2024.2390416

Tashunka Taylor-Miller, Ravi Savarirayan

{"title":"Progress in managing children with achondroplasia.","authors":"Tashunka Taylor-Miller, Ravi Savarirayan","doi":"10.1080/17446651.2024.2390416","DOIUrl":"10.1080/17446651.2024.2390416","url":null,"abstract":"Introduction: Achondroplasia is a heritable disorder of the skeleton that affects approximately 300,000 individuals worldwide. Until recently, treatment for this condition has been purely symptomatic. Efficacious treatment options for children are now approved or are in clinical trials.Areas covered: This review discusses key advances in the therapeutic management of children with achondroplasia, including vosoritide, the first approved drug, and other emerging precision therapies. These include navepegritide, a long-acting form of C-type natriuretic peptide, and infigratinib, a tyrosine kinase receptor inhibitor, summarizing trial outcomes to date.Expert opinion: The advent of the first approved precision therapy for achondroplasia in vosoritide has been a paradigm shifting advance for children affected by this condition. In addition to changing their natural growth history, it is hoped that it will decrease their medical complications and enhance functionality. These new treatment options highlight the importance of prompt prenatal identification and subsequent testing of a suspected fetus with achondroplasia and counseling of families. It is hoped that, in the near future, families will have the option to consider a range of effective targeted therapies that best suit their child with achondroplasia, starting from birth should they choose.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"479-486"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management. 替扎帕肽：揭开糖尿病和肥胖症双靶向治疗的新篇章。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-08-28 DOI: 10.1080/17446651.2024.2395540

Syed Arman Rabbani, Mohamed El-Tanani, Ismail I Matalka, Imran Rashid Rangraze, Alaa A A Aljabali, Mohammad Ahmed Khan, Murtaza M Tambuwala

{"title":"Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.","authors":"Syed Arman Rabbani, Mohamed El-Tanani, Ismail I Matalka, Imran Rashid Rangraze, Alaa A A Aljabali, Mohammad Ahmed Khan, Murtaza M Tambuwala","doi":"10.1080/17446651.2024.2395540","DOIUrl":"10.1080/17446651.2024.2395540","url":null,"abstract":"Introduction: Incretin-based therapies have emerged as effective treatments for type 2 diabetes (T2D) and obesity. However, not all patients achieve optimal outcomes with existing treatments, highlighting the need for more effective solutions.Areas covered: We present a comprehensive evaluation of Tirzepatide (TZP), a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, for managing obesity and T2D. We conducted a systematic search of Cochrane, PubMed, Scopus, and Web of Science databases from inception to April 2024. The focus of the review is on the development and therapeutic potential of TZP, with detailed exploration on pharmacodynamics, pharmacokinetics, clinical efficacy, and safety. Furthermore, it reviews TZP's impacts on glycemic control, weight management, and its potential cardiovascular (CV) benefits.Expert opinion: TZP represents a significant advancement in the dual-targeted approach to treating T2D and obesity. Its unique mechanism of action offers superior efficacy in reducing glycemic levels and body weight compared to existing therapies. New data suggesting improvements in CV outcomes indicate that TZP could set a new standard in the treatment paradigm. While long-term data on efficacy and safety are still forthcoming, current evidence positions TZP as a promising option for patients who have not reached their therapeutic goals with existing treatments.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"487-505"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is there a target value for time in tight range for individuals with type 1 diabetes on MDI? Data from masked CGM. 对使用 MDI 的 1 型糖尿病患者而言，是否有时间在严格范围内的目标值？数据来自遮蔽式 CGM。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-09-05 DOI: 10.1080/17446651.2024.2400487

Takayuki Ohno, Daisuke Tsujino, Rimei Nishimura

{"title":"Is there a target value for time in tight range for individuals with type 1 diabetes on MDI? Data from masked CGM.","authors":"Takayuki Ohno, Daisuke Tsujino, Rimei Nishimura","doi":"10.1080/17446651.2024.2400487","DOIUrl":"10.1080/17446651.2024.2400487","url":null,"abstract":"Objective: Time in Tight Range (TITR), defined as the percentage of time within the glucose range of 70 to 140 mg/dL, is anticipated to be challenging to maintain without causing hypoglycemia, especially in individuals with type 1 diabetes (T1D). This study aimed to investigate the TITR target value in individuals with T1D on multiple daily injections (MDI).Methods: The study included 101 individuals with T1D on MDI aged 15 to 75 who were hospitalized at Jikei University School of Medicine from September 2006 to November 2013 to conduct Continuous Glucose Monitoring (CGM). The cutoff values of TITR for predicting the attainment of GMI < 7.0%, and TBR < 4% were determined using Receiver Operating Characteristic (ROC) curves.Results: The TITR cutoff value was calculated to be 41% (sensitivity 81%, specificity 88%) and 40% (54%,72%) for predicting GMI < 7.0% and TBR < 4%.Conclusions: In individuals with T1D on MDI without devices capable of preventing hypoglycemia, it is recommended to target TITR at 40% to address the risk of increased hypoglycemia sufficiently.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"507-512"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The utility of a machine learning model in identifying people at high risk of type 2 diabetes mellitus. 机器学习模型在识别 2 型糖尿病高危人群方面的实用性。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-11-01 Epub Date: 2024-09-08 DOI: 10.1080/17446651.2024.2400706

Abdullah Alkattan, Abdullah Al-Zeer, Fahad Alsaawi, Alanoud Alyahya, Raghad Alnasser, Raoom Alsarhan, Mona Almusawi, Deemah Alabdulaali, Nagla Mahmoud, Rami Al-Jafar, Faisal Aldayel, Mustafa Hassanein, Alhan Haji, Abdulrahman Alsheikh, Amal Alfaifi, Elfadil Elkagam, Ahmed Alfridi, Amjad Alfaleh, Khaled Alabdulkareem, Nashwa Radwan, Edward W Gregg

{"title":"The utility of a machine learning model in identifying people at high risk of type 2 diabetes mellitus.","authors":"Abdullah Alkattan, Abdullah Al-Zeer, Fahad Alsaawi, Alanoud Alyahya, Raghad Alnasser, Raoom Alsarhan, Mona Almusawi, Deemah Alabdulaali, Nagla Mahmoud, Rami Al-Jafar, Faisal Aldayel, Mustafa Hassanein, Alhan Haji, Abdulrahman Alsheikh, Amal Alfaifi, Elfadil Elkagam, Ahmed Alfridi, Amjad Alfaleh, Khaled Alabdulkareem, Nashwa Radwan, Edward W Gregg","doi":"10.1080/17446651.2024.2400706","DOIUrl":"10.1080/17446651.2024.2400706","url":null,"abstract":"Background: According to previous reports, very high percentages of individuals in Saudi Arabia are undiagnosed for type 2 diabetes mellitus (T2DM). Despite conducting several screening and awareness campaigns, these efforts lacked full accessibility and consumed extensive human and material resources. Thus, developing machine learning (ML) models could enhance the population-based screening process. The study aims to compare a newly developed ML model's outcomes with the validated American Diabetes Association's (ADA) risk assessment regarding predicting people with high risk for T2DM.Research design and methods: Patients' age, gender, and risk factors that were obtained from the National Health Information Center's dataset were used to build and train the ML model. To evaluate the developed ML model, an external validation study was conducted in three primary health care centers. A random sample (N = 3400) was selected from the non-diabetic individuals.Results: The results showed the plotted data of sensitivity/100-specificity represented in the Receiver Operating Characteristic (ROC) curve with an AROC value of 0.803, 95% CI: 0.779-0.826.Conclusions: The current study reveals a new ML model proposed for population-level classification that can be an adequate tool for identifying those at high risk of T2DM or who already have T2DM but have not been diagnosed.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"513-522"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The complex web of obesity: from genetics to precision medicine. 肥胖症的复杂网络：从遗传学到精准医学。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-09-01 Epub Date: 2024-06-13 DOI: 10.1080/17446651.2024.2365785

Janaki Nair M, Dwaipayan Bharadwaj

{"title":"The complex web of obesity: from genetics to precision medicine.","authors":"Janaki Nair M, Dwaipayan Bharadwaj","doi":"10.1080/17446651.2024.2365785","DOIUrl":"10.1080/17446651.2024.2365785","url":null,"abstract":"Introduction: Obesity is a growing public health concern affecting both children and adults. Since it involves both genetic and environmental components, the management of obesity requires both, an understanding of the underlying genetics and changes in lifestyle. The knowledge of obesity genetics will enable the possibility of precision medicine in anti-obesity medications.Areas covered: Here, we explore health complications and the prevalence of obesity. We discuss disruptions in energy balance as a symptom of obesity, examining evolutionary theories, its multi-factorial origins, and heritability. Additionally, we discuss monogenic and polygenic obesity, the converging biological pathways, potential pharmacogenomics applications, and existing anti-obesity medications - specifically focussing on the leptin-melanocortin and incretin pathways. Comparisons between childhood and adult obesity genetics are made, along with insights into structural variants, epigenetic changes, and environmental influences on epigenetic signatures.Expert opinion: With recent advancements in anti-obesity drugs, genetic studies pinpoint new targets and allow for repurposing existing drugs. This creates opportunities for genotype-informed treatment options. Also, lifestyle interventions can help in the prevention and treatment of obesity by altering the epigenetic signatures. The comparison of genetic architecture in adults and children revealed a significant overlap. However, more robust studies with diverse ethnic representation is required in childhood obesity.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"403-418"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A retrospective study comparing the results of continuous glucose monitoring to self-blood glucose monitoring for pregnant women with type 1 diabetes mellitus. 一项回顾性研究，比较了对 1 型糖尿病孕妇进行连续血糖监测和自我血糖监测的结果。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-09-01 Epub Date: 2024-05-13 DOI: 10.1080/17446651.2024.2354471

Adeel Ahmad Khan, Fateen Ata, Naglaa Abdelaleem Al Sayed Alsharkawy, Eman Mahmoud Mohamed Othman, Ifrah Mohamed Hassan, Faten Altaher Mohd Taha, Khaled Baagar, Hamda Ali, Jutin C Konje, Abdul Badi Abou-Samra, Mohammed Bashir

{"title":"A retrospective study comparing the results of continuous glucose monitoring to self-blood glucose monitoring for pregnant women with type 1 diabetes mellitus.","authors":"Adeel Ahmad Khan, Fateen Ata, Naglaa Abdelaleem Al Sayed Alsharkawy, Eman Mahmoud Mohamed Othman, Ifrah Mohamed Hassan, Faten Altaher Mohd Taha, Khaled Baagar, Hamda Ali, Jutin C Konje, Abdul Badi Abou-Samra, Mohammed Bashir","doi":"10.1080/17446651.2024.2354471","DOIUrl":"10.1080/17446651.2024.2354471","url":null,"abstract":"Background: Type 1 diabetes mellitus (T1DM) is associated with adverse maternal and fetal outcomes. Continuous glucose monitoring (CGM) during pregnancy is associated with better glycemic control in women with T1DM. However, no clear benefits have been demonstrated in reducing adverse feto-maternal outcomes in pregnant women with T1DM.Design and methods: This is a retrospective, single-center study of pregnant women with T1DM to evaluate the impact of CGM use on glycemic control and feto-maternal outcomes in pregnant women with T1DM.Results: Of 265 women with T1DM, 92 (34.7%) used CGM, and 173 (65.3%) were managed with capillary blood glucose (CBG) monitoring. The mean (SD) age and BMI at the first visit were 29.4 (4.7) years and 27.2 (5.2) kg/m2, respectively. The mean (SD) HbA1c at the first-trimester visit was 63 (1) mmol/mol, and in the last trimester was 51 (1%). There was no difference in the mean changes in HbA1c between the two groups. Women using CGM had lower insulin requirements (1.02 + 0.37 vs. 0.87 + 0.04 units/kg, p = 0.01). The two groups had no significant differences in maternal or fetal outcomes.Conclusion: CGM use in pregnant T1DM women is not associated with improved fetomaternal outcomes.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"429-435"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temporal trends on the prevalence of renal disease and outcomes among patients with diabetes mellitus hospitalized by heart failure: findings from INCAex. 因心力衰竭住院的糖尿病患者中肾病患病率和预后的时间趋势：INCAex 的研究结果。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1080/17446651.2024.2365769

José Carlos Arévalo-Lorido, Juana Carretero-Gomez, Alessia Rubini, Francisco Javier Félix-Redondo, Nicolás Roberto Robles Pérez Monteoliva, Miriam Hernández González, Elena Vázquez Jarén, Bárbara Cancho-Castellanos, Reyes González Fernández, Daniel Fernández-Bergés

{"title":"Temporal trends on the prevalence of renal disease and outcomes among patients with diabetes mellitus hospitalized by heart failure: findings from INCAex.","authors":"José Carlos Arévalo-Lorido, Juana Carretero-Gomez, Alessia Rubini, Francisco Javier Félix-Redondo, Nicolás Roberto Robles Pérez Monteoliva, Miriam Hernández González, Elena Vázquez Jarén, Bárbara Cancho-Castellanos, Reyes González Fernández, Daniel Fernández-Bergés","doi":"10.1080/17446651.2024.2365769","DOIUrl":"10.1080/17446651.2024.2365769","url":null,"abstract":"Background: To assess 20-year time trends in the prevalence of diabetes mellitus (DM) among inpatients with heart failure (HF) and the influence of coexisting DM and kidney disease (KD) on outcomes.Research design and methods: A retrospective study of patients was admitted due to HF, during the period 2000/2019. The period of follow-up was divided into three intervals according to the European Medical Agency approval of newer hypoglycemic drugs. We analyzed in-hospital mortality and outcomes during the follow-up period.Results: A total of 4959 patients were included. Over time, prevalence of DM was significantly raising among women with HF (50 to 53.2%) and descending among men (50% to 46.8%, p = 0.02). Total mortality and readmissions were higher in patients with DM during the and second periods. However, no significant differences were found in the third-one (HR 1.14, 95% CI 0.94-1.39, p = 0.181). A protector role of oral hypoglycemic medications was observed in this last period. According to the presence of KD, the patients with both DM and KD were who presented most of the events.Conclusions: Over the time analyzed, the prevalence of DM raised among women and decreased among men. DM influenced the prognosis of HF except in the third period when more protective hypoglycemic drugs started to be used.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"447-457"},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A social movement: mind the gap in women's healthcare and research. 社会运动：关注妇女保健和研究方面的差距。

IF 2.7

Expert Review of Endocrinology & Metabolism Pub Date : 2024-09-01 Epub Date: 2024-06-10 DOI: 10.1080/17446651.2024.2365790

Lawrence M Nelson

引用次数: 0